BSTC BioSpecifics Technologies Corp

47.46
+0.72  (2%)
Previous Close 46.74
Open 47.13
Price To book 5.47
Market Cap 340014498
Shares 7,164,233
Volume 20,294
Short Ratio 5.58
Av. Daily Volume 24,249

SEC filingsSee all SEC filings

  1. 8-K - Current report 171083520
  2. 8-K - Current report 171018838
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171018423
  4. 8-K - Current report 17916194
  5. 8-K - Current report 17901037

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Endo is currently performing a commercial assessment.
XIAFLEX
Plantar fibromatosis
Phase 2 topline data released June 2016 - endpoints met
XIAFLEX
Human lipomas
Phase 2b data released November 17, 2016. Met endpoints. Phase 3 planned for toward the end of 2017.
XIAFLEX
Edematous fibrosclerotic panniculopathy (“cellulite”)
Phase 2b trial did not meet endpoint. Endo is currently performing a commercial assessment.
XIAFLEX
Adhesive Capsulitis (“Frozen Shoulder syndrome”)

Latest News

  1. Biospecifics Technologies Corp. breached its 50 day moving average in a Bearish Manner : BSTC-US : October 18, 2017
  2. Biospecifics Technologies Corp. breached its 50 day moving average in a Bullish Manner : BSTC-US : October 3, 2017
  3. One Thing To Consider Before Buying BioSpecifics Technologies Corp (BSTC)
  4. BioSpecifics Technologies Corp. to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
  5. Biospecifics Technologies Corp. breached its 50 day moving average in a Bearish Manner : BSTC-US : September 18, 2017
  6. Should You Buy BioSpecifics Technologies Corp (BSTC) At This PE Ratio?
  7. Biospecifics Technologies Corp. :BSTC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017
  8. New Strong Sell Stocks for September 5th
  9. BioSpecifics Technologies Corp. to Present at Two Upcoming September Conferences
  10. New Strong Sell Stocks for August 21st
  11. BioSpecifics posts 2Q profit
  12. BioSpecifics Technologies Corp. Reports Second Quarter 2017 Financial Results
  13. Biospecifics Technologies Corp. – Value Analysis (NASDAQ:BSTC) : August 4, 2017
  14. Biospecifics Technologies Corp. breached its 50 day moving average in a Bullish Manner : BSTC-US : July 21, 2017
  15. ETFs with exposure to Biospecifics Technologies Corp. : July 11, 2017
  16. ETFs with exposure to Biospecifics Technologies Corp. : June 19, 2017
  17. Biospecifics Technologies Corp. :BSTC-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017
  18. BioSpecifics Technologies Corp. to Present at the Jefferies 2017 Healthcare Conference
  19. Pharma Stock With Triple-Digit Growth Forming Blotchy Base

SEC Filings

  1. 8-K - Current report 171083520
  2. 8-K - Current report 171018838
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171018423
  4. 8-K - Current report 17916194
  5. 8-K - Current report 17901037
  6. 8-K - Current report 17831420
  7. 8-K - Current report 17831404
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 17830954
  9. DEF 14A - Other definitive proxy statements 17796255
  10. 8-K - Current report 17773215